News Roundup

  • Vizient Announces Strategic Partnership With Phrase Health to Enable Real-Time Insights Into Provider Ordering Practices; Clinician Decision Analytics will drive quality and cost improvement—Vizient has announced a strategic agreement with Phrase Health, a clinical process improvement analytics company, to offer quality improvement workflow and process solutions for improving patient outcomes. The partnership provides a platform for Vizient’s Clinician Decision Analytics offering, which will enable Vizient member health care organizations to capture near real-time data from electronic health records and gain insights into clinician ordering practices. More via Vizient newsroom
  • AHA to Congress: Hospitals Need More Resources Amid Financial Struggles—"...The American Hospital Association and seven other hospital organizations including Vizient have penned a letter urging Congress to provide additional resources to help hospitals address ongoing operational and financial struggles during the COVID-19 pandemic. More via RevCycleIntelligence
  • Vizient Tech Watch Lays Out Trends in Diagnostic Imaging Strategy, Reviews Technologies—Vizient released its latest Diagnostic Imaging Tech Watch, which reviews the latest trends in health care imaging technology. The report is collection of articles offering data-driven insights and perspectives from Vizient subject matter experts, focuses on trends in diagnostic imaging strategy and advancements in technology for X-ray and magnetic resonance imaging (MR). More via Vizient newsroom  
  • Maternal Mortality: Rare but Too Common—"...By some estimates, American women today are 50% percent more likely to die because of pregnancy-related health issues than their mothers were, notes Vizient’s Courtney Furrow-White, M.P.M., RN. More via Managed Healthcare Executive
  • Vizient: Drug prices for hospitals to increase 3% in 2022, with remdesivir topping adalimumab in total spend—"...'Before COVID, we anticipated adalimumab would remain the top drug by total spend until biosimilars are introduced to bring in competition in 2023,' says Vizient’s Dan Kistner. 'That remdesivir replaced it as the [number one] drug in total member spend across all classes of trade reflects how COVID has impacted hospitals and the unanticipated costs to their budgets.'..." More via Fierce Healthcare

Blogs you May Have Missed

Published: March 22, 2022